Cosmo Pharmaceuticals NV

C43

Company Profile

  • Business description

    Cosmo Pharmaceuticals NV is a pharmaceutical company with a focus on gastrointestinal diseases, dermatology and healthtech. The company develops and manufactures products that are distributed globally by its partners. Products that the company has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers' diarrhoea (TD) and Winlevi for the treatment of acne. Product pipeline includes Breezula, GI Genius, Methylene blue MMX, Aemcolo, CB-03-10 and CB-01-33.

  • Contact

    Sir John Rogerson’s Quay
    Riverside II
    Dublin2
    IRL

    T: +353 18170370

    E: [email protected]

    https://www.cosmopharma.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - General

    Fiscal Year End

    31 December 2025

    Employees

    339

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,053.20142.30-1.74%
CAC 407,834.6681.42-1.03%
DAX 4022,260.73200.79-0.89%
Dow JONES (US)41,583.90715.80-1.69%
FTSE 1008,593.1665.69-0.76%
HKSE23,119.58307.02-1.31%
NASDAQ17,322.99481.04-2.70%
Nikkei 22535,617.561,502.77-4.05%
NZX 50 Index12,270.0017.46-0.14%
S&P 5005,580.94112.37-1.97%
S&P/ASX 2007,843.40138.60-1.74%
SSE Composite Index3,335.7515.56-0.46%

Market Movers